Posaconazole reduces infection in AML patients

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 18 No 10
Volume 18
Issue 10

The incidence of pneumonia and invasive pulmonary aspergillosis in acute myeloid leukemia patients was reduced when they were given posaconazole (Noxafil) as prophylaxis.

The incidence of pneumonia and invasive pulmonary aspergillosis in acute myeloid leukemia patients was reduced when they were given posaconazole (Noxafil) as prophylaxis.

According to a study presented at the 2009 Interscience Conference on Antimicrobial Agents and Chemotherapy in San Francisco, the number of febrile days, incidence rates of invasive fungal diseases and aspergillosis, and duration of hospitalization decreased significantly (abstract 1052).

Recent Videos
4 experts in this video
2 experts in this video
2 experts in this video
4 experts in this video
Ongoing studies seek to evaluate immunotherapy in earlier lines of therapy for patients with early-stage Hodgkin lymphoma.
Strict inclusion criteria may disproportionately exclude racial minority populations from participating in breast cancer trials.
A paucity of prospective, well-vetted data to guide therapy in patients with rare lymphomas may result in a reliance on expert consensus guidelines.
Related Content